Better 5-Year Valve Performance With TAVI Than Surgery

by

TOPLINE:

In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter aortic valve implantation (TAVI) was associated with a lower 5-year incidence of bioprosthetic valve dysfunction than surgery. Valve dysfunction was also associated with an increased risk for death and hospitalization, regardless of replacement therapy.

METHODOLOGY:

  • Researchers conducted a post hoc analysis to compare the valve performances between patients with symptomatic severe aortic stenosis who underwent CoreValve or Evolut TAVI with Medtronic devices and those who underwent surgery.
  • They formed a cohort of 5606 patients (mean age, 82.2 years; 45.2% women) that included those from randomized controlled trials who underwent CoreValve, Evolut TAVI, or surgery and those from…

Source link

Related posts:

  1. Remimazolam-Flumazenil Combo Cuts Extubation Time in TAVI
  2. Rethinking the Timing of Tricuspid Valve Repairs
  3. First Hours Crucial in New Guidance for Cardiogenic Shock
  4. New Cardiology Board Dispute Intensifies at Town Hall

Leave a Comment